

Effective June 8, 2021

Inpatient Providers

# Order J&J COVID-19 vaccine for inpatient administration

Providers with prescribing rights can order the [Johnson & Johnson](#) (Janssen), one-shot COVID-19 vaccine for inpatients 18 years and older at main campus, Akron General, Avon, Fairview, Euclid, Hillcrest, Lutheran, Marymount, Medina and South Pointe hospitals.

The **COVID-19 vaccine .5ml (PF) (JANSSEN) [174824]** order will be available as of May 25 on main campus preference lists. This order must be placed by a licensed independent practitioner (LIP), it cannot be ordered by a nurse.

The order frequency will default to once at 5pm to align with vaccine storage and administration workflows.

**COVID-19 vaccine 0.5 mL (PF) (JANSSEN)** [Accept] [Cancel]

Order Inst: Janssen COVID-19 vaccine is a single dose product. Cannot be used to complete a series that began with Pfizer or Moderna.

Reference Links: 1. Drug Info - Adult 2. Drug Info - Peds 3. EUA Fact Sheet  
4. Ohio SIS Registry 5. FLW - Shots Registry

Priority: [Search]

Dose: 1 Syringe 1 Syringe

Administer Dose: 1 Syringe  
Administer Amount: 0.5 mL

Route: INTRAMUSCULAR INTRAMUSCULAR

Frequency: ONCE AT 5PM ONCE AT 5PM

For: 1 [Doses] [Hours] [Days]

Starting: 5/20/2021 [Today] [Tomorrow]

First Dose: [Include Now] [As Scheduled]

First Dose: **Today 1700** Last Dose: **Today 1700** Number of doses: 1

Scheduled Times: 05/20/21 1700

Admin. Inst.: Document Lot Number and Expiration Date from CDC COVID-19 Vaccination Record Card

Prod. Admin. Inst.: EXP: (6 HR) - Refrigerate - Protect from light

Dx Assoc.: Associate diagnoses

Dispense: Dispense from: CC PHARMACY MAIN First doses from: CC PHARMACY MAIN

Product: COVID-19 VACCINE, AD26.COV2.S (JANSSEN)(PF) 0.5 ML Package: 0.5 mL Syringe (99999-086-4)

IM SUSPENSION (EUA) [174824] [Dispense package x 1]

Dispense amount: 0.5 mL

Charge method: MINIMUM CHARGE Dispense code: IV Syringe

Dispense every [ ] hours Label comments: + Add Label Comments

Do not dispense [ ] doses

[Next Required] Link Order [Accept] [Cancel]

## Clinical criteria for inpatient vaccination and provider talking points

- Considerations for vaccine deferral per the Advisory Committee on Immunization Practices and Centers for Disease Control and Prevention recommendations and clinical experts

<p><b>Absolute Contraindications</b></p> <ul style="list-style-type: none"> <li>- Acute infection with COVID-19</li> <li>- Treatment of COVID-19 infection with convalescent plasma or COVID-19 directed monoclonal antibodies within the past 90 days <ul style="list-style-type: none"> <li>• Examples: bamlanivimab, etesevimab, casirivimab, imdevimab</li> </ul> </li> </ul>
<p><b>Precautions:</b> consider deferring vaccination or vaccinate on case-by-case basis</p> <ul style="list-style-type: none"> <li>- Surgical procedure anticipated within the next 72 hours</li> <li>- Solid organ or bone marrow transplantation, CAR-T cell therapy: delay vaccination for 3 months</li> <li>- Admission for chemotherapy treatment</li> <li>- Receipt of rituximab or treatment for acute rejection within past 6 months</li> <li>- Acute illness including sepsis or septic shock</li> </ul>

- The Johnson & Johnson (Janssen) vaccine is the third vaccine to get authorized for emergency use in the US and only requires one dose.
- It is authorized for emergency use by the FDA, for individuals age **18** and over.
- In the phase 3 clinical trial, the vaccine was shown to be **66%** effective in preventing moderate and severe COVID-19 disease 28 days after vaccination. Overall, the vaccine was also **85%** effective in preventing hospitalization and **100%** effective in preventing death, 28 days after vaccination.
- **Women aged < 50 years** can receive any FDA-authorized COVID-19 vaccine. However, they should be aware of the rare risk of thrombosis with thrombocytopenia syndrome (TTS) after receipt of the J&J vaccine and the availability of other FDA-authorized COVID-19 vaccines (i.e., mRNA vaccines). The highest rates of TTS per vaccine doses administered were identified in women <50 years of age. At the time of ACIP's review, TTS reporting rates to VAERS were 7.0 cases per million Janssen COVID-19 vaccine doses administered to women ages 18–49 years and 0.9 per million to women aged ≥50 years.
- Use was paused to review a small number of clotting events with low platelet counts in the U.S.
- The FDA recommended resuming the use of the vaccine as the events were deemed extremely rare, happening to a small percentage of people out of the 8 million who received the vaccine at the time of the pause.
- All of the cases occurred in women between the ages of 18 and 59 and symptoms occurred six to 15 days after vaccination.
- Patients and can monitor for headaches, stomach pain, leg pain or shortness of breath two to three weeks after getting the vaccine. Patients should contact a healthcare provider immediately if experiencing these symptoms in the two to three weeks following vaccination.
- The CDC has issued guidance on public health recommendations for those who are fully vaccinated from COVID-19. Individuals are considered fully vaccinated two weeks after receiving the Johnson & Johnson vaccine.